Industries > Pharma > Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024

Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024

PUBLISHED: 09 June 2014
PAGES: 189
PRODUCT CODE:
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

Kinase inhibitors – a new study showing you trends, R&D and predicted revenues
Do you want to find sales potentials of kinase inhibitors? Now get the latest analysis for those cancer treatments. There you explore developments, other trends, results, opportunities and revenue forecasts.

Visiongain’s new report shows you what’s possible for drugs using protein kinase inhibition and related technology. There avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales. See now how you can gain.

You assess trends, technologies and products, benefiting your reputation for technological, medical and commercial insight.

Progress of that industry – see what’s possible for those anti-cancer medicines
There you explore the future of those therapies. Read on to investigate that industry and see how high its future sales could go.

Forecasts and other information showing technical, clinical and commercial possibilities
That new study gives you sales predictions to 2024 at overall world market, submarket, company, product and national level. See what the future holds. For those drugs you investigate where demand and money lie.

There hear what’s possible. And avoid struggles to find information. Besides giving revenue predictions, that new analysis shows historical results, growth rates and market shares.

In that work you discover 77 tables, 81 charts and an interview with a company. There help your research, analyses and decisions, also benefiting your influence.

And the following sections explain what our new investigation gives you.

Forecasting of that world market and its segments
What’s the potential of that biomedical industry? What’re the secrets of its progress? Find in our report overall world revenue to 2024 from inhibition of protein kinases.

There also find individual revenue predictions to 2024 – with discussions – for seven submarkets at world level:
• Bcr-Abl inhibitors
• Angiogenesis inhibitors
• EGFR inhibitors
• mTOR inhibitors
• Other kinase agents
• BRAF and MEK products
• Generic drugs (generics) and related medicines.

You assess outlooks for expansion in trade, hearing where potential sales increases exist. That work investigates products, uses and revenues past and future. Find what’s possible.

Our study also explores competition. There you see what’s happening for developers, producers and sellers of kinase inhibiting agents, understanding challenges, trends and outlooks. You also explore revenues by product.

Drug forecasts – existing and expected therapies
Discover sales potentials for leading brands, too, seeing how they can compete and succeed. How will 35 cancer treatments perform to 2024 at world level?

Our work shows you individual revenue predictions for 24 top products, including Gleevec, Sprycel, Tasigna, Tarceva and Iressa. It also gives sales predictions for 11 expected drugs, including Palbociclib, Bemaciclib, Alectinib, Ceritinib and Idelalisib.

Also that work splits its overall world market into geographical forecasts.

Healthcare in national markets – what outlooks for that business?
Advances in pharmaceutical biotechnology and healthcare expand use of anti-cancer drugs, including kinase inhibitors. See prospects for developed and developing regions.

Our analyses show you individual revenue forecasts to 2024 for 11 countries:
• United States (US)
• Japan
• Germany, France, UK, Italy and Spain (EU5), also with overall EU prediction
• Brazil, Russia, India and China (BRIC nations).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

Also how do events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies and trends.

Forces affecting developers, producers and sellers of those pharmaceuticals
The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these:
• Scope of protein kinases in oncology – R&D from 2014
• Cyclin-dependent kinase 4/6 inhibitors in development
• Anaplastic lymphoma kinase (alk) compounds in testing
• Bruton’s tyrosine kinase and PI3K agents for the future
• MEK and BRAF inhibition and other mechanisms of action.

And you explore these trends and influences, among others:
• Drug delivery technology to benefit products’ performance and use
• Stratification of patients for clinical and commercial benefits
• Generic competition for small-molecule treatments
• Biological drugs (biologics) – including monoclonal antibodies (mAbs) – giving differentiated mechanisms of action
• Therapeutic targets identified through cancer genomics – scope for novel technologies
• Combination therapies – potential for improvements in treating patients.

There you assess that industry’s strengths, weaknesses, opportunities and threats, also exploring social, technological, economic and political questions. And you get Porter’s Five Forces analysis. Those methods give you feel for that industry, its progress and potential.

You explore what progress, trends and prospects mean. And you discover what benefits and restricts companies, affecting commercial performance.

Kinase inhibitors for cancer – what 2018 market value?
What happens next? From 2014, kinase inhibitors for cancer patients hold great potential for investments, technological advances and sales. Our new report predicts the world market for those products will reach $27.8bn in 2018, with further expansion to 2024.

In particular our study explores activities and potentials of these companies, including individual revenue forecasting to 2024:
• Novartis
• Pfizer
• Roche
• Bristol-Myers Squibb
• Bayer
• GlaxoSmithKline (GSK)
• AstraZeneca.

From 2014 large pharmaceutical firms and biopharma specialists will win in that market. See how, discovering organisations’ potentials.

Ways Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 helps
In three main ways our investigation helps your work:
Revenues to 2024 at world level, for 7 submarkets, 6 companies and 35 products – assess outlooks for production, marketing and sales
Forecasts to 2024 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for potential revenues
Prospects of established competitors, rising companies and new entrants – explore activities, results, news, opinions, R&D and outlooks for success.

Knowledge there found nowhere else, benefiting your research, analyses and plans
Our work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.

With that investigation you’re less likely to fall behind in information or miss opportunity. Discover there how you can benefit your data searches, analyses and decisions, also saving time and helping you gain in authority.

That new study is for everyone assessing the present and future of kinase inhibition and related biotechnology. There you find results, trends, opportunities and sales predictions. So please get that report here now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024


Download sample pages

Complete the form below to download your free sample pages for Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories